Compare Abbott Laboratories (ABT) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Nano Dimension Ltd - ADR — how do they compare? Abbott Laboratories trades at $95.38 (market cap $166.94B), while Nano Dimension Ltd - ADR trades at $1.5 (market cap $307.34M). The key difference: Abbott Laboratories is far larger — about 543.2× Nano Dimension Ltd - ADR's market cap, and Abbott Laboratories pays a 2.63% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| ABT | NNDM | |
|---|---|---|
Market Cap | $166.94B | $307.34M |
Sector | Health | Technology |
52-Week High | $136.62 | $2.14 |
52-Week Low | $82.57 | $1.21 |
Enterprise Value | $193.69B | -$102.00M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Nano Dimension (NNDM) trades at $1.46, up 0.69% on the day, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $102.44M but a net loss of $293.30M, with negative cash flow from operations of $101.28M. Recent news highlights a proposed business combination with Infinite Epigenetics and ongoing shareholder disputes with Murchinson Ltd., reflecting strategic shifts and internal tensions.
Outlook remains challenged by persistent losses and cash burn, though the low P/B of 0.63 may attract value investors. Key risks include execution of the strategic plan, shareholder approval of the Infinite Epigenetics deal, and achieving profitability. Opportunities lie in cost reductions and potential synergies from mergers, but the stock faces significant fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
